CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer

[1]  F W MULSOW,et al.  Cancer incidence and mortality , 2019, Health at a Glance: Europe.

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  S. Choi,et al.  Additive endoscopic resection may be sufficient for patients with a positive lateral margin after endoscopic resection of early gastric cancer. , 2017, Gastrointestinal endoscopy.

[4]  M. Zhou,et al.  Trend analysis of cancer incidence and mortality in China , 2017, Science China Life Sciences.

[5]  Jie He,et al.  Cancer incidence and mortality in China, 2013. , 2017, Cancer letters.

[6]  J. Kirkwood,et al.  Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity , 2017, Cell.

[7]  Masahiro Ito,et al.  A decrease in the prognostic nutritional index is associated with a worse long-term outcome in gastric cancer patients undergoing neoadjuvant chemotherapy , 2017, Surgery Today.

[8]  Mohsen Naghavi,et al.  Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014 , 2017, JAMA.

[9]  Lai-han Leung,et al.  Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis , 2016, Journal of Hematology & Oncology.

[10]  J. Ji,et al.  Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials. , 2016, Cancer letters.

[11]  D. Cunningham,et al.  Encouraging results for PD-1 inhibition in gastric cancer. , 2016, The Lancet. Oncology.

[12]  J. Lunceford,et al.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. , 2016, The Lancet. Oncology.

[13]  M. Hattori,et al.  Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers , 2016, Nature Medicine.

[14]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[15]  F. Roviello,et al.  Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. , 2016, Cancer letters.

[16]  Deepali V. Sawant,et al.  Interleukin-35 Limits Anti-Tumor Immunity. , 2016, Immunity.

[17]  Nikhil S. Joshi,et al.  Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. , 2015, Immunity.

[18]  E. Raz,et al.  Chemokine‐guided cell migration and motility in zebrafish development , 2015, The EMBO journal.

[19]  C. Meyer,et al.  Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients , 2015, Proceedings of the National Academy of Sciences.

[20]  Nir S. Gov,et al.  Collective Cell Motility Promotes Chemotactic Prowess and Resistance to Chemorepulsion , 2015, Current Biology.

[21]  Naotoshi Sugimoto,et al.  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[22]  S. Sakaguchi,et al.  Regulatory T cells in cancer immunotherapy. , 2014, Current opinion in immunology.

[23]  Ke Chen,et al.  Short-term surgical and long-term survival outcomes after laparoscopic distal gastrectomy with D2 lymphadenectomy for gastric cancer , 2014, BMC Gastroenterology.

[24]  Wolfgang Huber,et al.  Directional tissue migration through a self-generated chemokine gradient , 2013, Nature.

[25]  Zhiwei Zhen,et al.  CCR7 Expression and Intratumoral FOXP3+ Regulatory T Cells are Correlated with Overall Survival and Lymph Node Metastasis in Gastric Cancer , 2013, PloS one.

[26]  Antoni Ribas,et al.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. , 2013, The New England journal of medicine.

[27]  L. Zitvogel,et al.  Following up tumor-specific regulatory T cells in cancer patients , 2013, Oncoimmunology.

[28]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[29]  T. Bakács,et al.  Ipilimumab (Yervoy) and the TGN1412 catastrophe. , 2012, Immunobiology.

[30]  S. Rai,et al.  Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma , 2011, BMC Cancer.

[31]  J. Wolchok,et al.  Novel cancer immunotherapy agents with survival benefit: recent successes and next steps , 2011, Nature Reviews Cancer.

[32]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[33]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[34]  A. Norman,et al.  Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.

[35]  A. Rudensky,et al.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice , 2007, Nature Immunology.

[36]  M. Beyer,et al.  Regulatory T cells in cancer. , 2006, Blood.

[37]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.